P2RX7 and inflammatory bowel disease: Clinical trials (Phase 1 and 2) to determine the safety and efficacy of P2X7 receptor antagonists in chronic inflammatory diseases (rheumatoid arthritis, inflammatory bowel disease) are presently in progress [reviewed in Arulkumaran et al. (2011)].